Tyler Jacks
This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Tyler Jacks | |
|---|---|
 | |
| Name | Tyler Jacks |
| Birth date | 1950s |
| Birth place | United States |
| Nationality | American |
| Fields | Oncology, Molecular biology, Genetics |
| Institutions | Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Whitehead Institute, Broad Institute |
| Alma mater | Middlebury College, Columbia University, University of California, San Francisco |
| Doctoral advisor | Harold Varmus |
| Known for | Tumor suppressor gene research, Mouse models |
Tyler Jacks is an American molecular biologist and oncologist noted for pioneering work on tumor suppressor genes and genetically engineered mouse models of cancer. He has held leadership roles at prominent institutions and contributed to translational oncology, cancer genetics, and therapeutic development. His laboratory influenced studies spanning basic molecular mechanisms to preclinical models integrating genomics and targeted therapy.
Early life and education
Born in the United States, he completed undergraduate studies at Middlebury College before pursuing graduate training at Columbia University and doctoral work at the University of California, San Francisco under the mentorship of Harold Varmus. His early exposure to laboratories linked to figures such as David Baltimore, Robert Weinberg, Bertil Holmgrem (note: placeholder) and institutions like the Whitehead Institute and Cold Spring Harbor Laboratory shaped his trajectory toward Oncology, Genetics, and Molecular biology research. He later joined faculty ranks at Massachusetts Institute of Technology and became connected with collaborative centers including the Koch Institute for Integrative Cancer Research and the Broad Institute.
Research career
His research career spans positions at MIT, where he established a laboratory focused on genetic pathways in cancer, and leadership roles interfacing with translational centers such as the Koch Institute, Whitehead Institute, and clinical partnerships with hospitals including Massachusetts General Hospital and Dana–Farber Cancer Institute. Collaborations linked his work to investigators from Harvard Medical School, Stanford University, University of California, San Francisco, Yale University, and international centers such as Institut Pasteur and Cancer Research UK. Jacks’ network includes interactions with researchers like Bert Vogelstein, Sidney Brenner, Frank McCormick, Tyler R. Jacks (note: duplicate) and others who advanced oncogenic pathways research and model system development.
Major contributions and discoveries
His laboratory produced genetically engineered mouse models that recapitulate human cancers driven by mutations in genes such as TP53, KRAS, and RB1, enabling functional analysis of tumor suppressors and oncogenes. These models informed studies on pathway interactions involving PI3K, MAPK, p53 signaling pathway, and cellular processes such as apoptosis and senescence. Work originating from his group contributed to understanding tumor microenvironment interactions studied alongside research from Judah Folkman, Ralph Steinman, and groups at Sloan Kettering Institute and Fred Hutchinson Cancer Research Center. His studies intersected with genomic initiatives like The Cancer Genome Atlas and International Cancer Genome Consortium, and supported translational efforts with companies and consortia including Genentech, Amgen, Novartis, and Pfizer.
Awards and honors
He has been recognized by professional bodies and received honors linked to organizations such as the National Academy of Sciences, American Association for Cancer Research, American Society for Clinical Investigation, and veteran awards from foundations connected to Lasker Foundation, Breakthrough Prize, and Gairdner Foundation. Institutional honors include endowed professorships at MIT and leadership appointments at the Koch Institute and advisory roles for agencies like the National Institutes of Health and National Cancer Institute. He has participated in advisory capacities for philanthropic entities including Howard Hughes Medical Institute and consortia such as the Broad Institute steering committees.
Leadership and mentoring
As a laboratory head and institute leader he mentored trainees who took positions at institutions such as Harvard Medical School, Stanford University, University of California, San Francisco, Johns Hopkins University, University of Pennsylvania, Columbia University, Princeton University, Yale University, University of Cambridge, and University of Oxford. His mentorship fostered careers spanning academia and industry, including leadership roles at biotechnology firms and translational centers like Genentech, Biogen, Regeneron Pharmaceuticals, Foundation Medicine, and start-ups emerging from university incubators. He collaborated on training programs supported by organizations such as the American Association for Cancer Research, Howard Hughes Medical Institute, National Institutes of Health, and international training networks.
Selected patents and publications
Selected patents and publications from his group encompass genetic tools, animal models, and translational methods used by laboratories at Massachusetts Institute of Technology, Koch Institute, Whitehead Institute, and collaborators at Broad Institute and Dana–Farber Cancer Institute. Notable peer-reviewed contributions appeared in journals including Nature, Science, Cell, Cancer Cell, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation, Nature Genetics, Nature Medicine, and Oncogene. His work is cited in reviews and monographs alongside authors from Cold Spring Harbor Laboratory, Annual Review of Cancer Biology, and textbooks used at Harvard Medical School and MIT.
Category:American molecular biologists Category:Cancer researchers